Tumor necrosis factor-α (TNF-α) is a proinflammatory cytokine. Agents that neutralize TNF-α are effective in the treatment of disorders such as rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), spondyloarthropathies, and inflammatory bowel disease. TNF-α antagonist therapy has been associated with the development of antinuclear antibodies (ANA) and double-stranded DNA (dsDNA) antibodies, as well as the infrequent development of systemic lupus erythematosus (SLE)-like disease. We describe the first case of biopsy-confirmed proliferative lupus nephritis and leuko-cytoclastic vasculitis in a patient treated with etanercept for JRA.
|Original language||English (US)|
|Number of pages||4|
|Journal||Journal of Rheumatology|
|State||Published - Apr 1 2005|
- Systemic lupus erythematosus
- Tumor necrosis factor
ASJC Scopus subject areas